This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Down-regulated expression of PTEN in colorectal cancer and its clinical significance
Ji Li, Su-Li Tian, Wei Li, Fu-Yun Li
Ji Li, Su-Li Tian, Wei Li, the Second Department of General Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin 150086, Heilongjiang Province, China
Fu-Yun Li, Anda Hospital of Chinese Medicine, Anda 151400, Heilongjiang Province, China
Correspondence to: Su-Li Tian, the Second Department of General Surgery, the Second Affiliated Hospital of Harbin Medical University, 157 Baojian Road, Harbin 150086, Heilongjiang Province, China. email@example.com
Received: May 20, 2006 Revised: May 25, 2006 Accepted: June 5, 2006 Published online: October 8, 2006
AIM: To study the expression of PTEN in colorectal carcinoma and its correlation with the clinicopathological features.
METHODS: Immunohistochemical SP technique was used to determine the expression of PTEN protein in 65 cases of colorectal carcinoma and their corresponding adjacent tissues, 13 cases of adenoma tissues, and 20 cases of normal colorectal tissues.
RESULTS: The expression of PTEN protein was mainly located in the nucleus and cytoplasm. The expression of PTEN protein was significantly lower in human colorectal cancer tissues than that in the corresponding adjacent tissues ones (56.92% vs 86.15%, P < 0.01), and it was also markedly lower in the lowly- and non-differentiated adenoma than that in the highly-and moderately-differentiated one (37.50% vs 75.76%, P < 0.01). The expression of PTEN protein in Dukes A and B stages were significantly higher than that in in Dukes C and D stages (73.33% vs 42.86%, P < 0.05). In addition, PTEN expression was correlated with lymph node metastasis (c2 = 7.448, P < 0.01), but not with the sex, tumor sizes of patients.
CONCLUSION: The expression of PTEN is down-regulated in colorectal carcinoma, and it may be one of the molecular and biological indicators in reflecting the progression and prognosis of colorectal cancer.
Key Words: Colorectal cancer; Cancer-adjacent tissue; Phosphatase and tension homolog deteted on chromosome ten; Metastasis
Citation: Li J, Tian SL, Li W, Li FY. Down-regulated expression of PTEN in colorectal cancer and its clinical significance. Shijie Huaren Xiaohua Zazhi 2006; 14(28): 2771-2775
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.Science. 1997;275:1943-1947.
Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer.Mod Pathol. 2001;14:672-676.
Leslie NR, Gray A, Pass I, Orchiston EA, Downes CP. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase.Biochem J. 2000;346 Pt 3:827-833.
Tolkacheva T, Chan AM. Inhibition of H-Ras transformation by the PTEN/MMAC1/TEP1 tumor suppressor gene.Oncogene. 2000;19:680-689.
Gao X, Neufeld TP, Pan D. Drosophila PTEN regulates cell growth and proliferation through PI3K-dependent and -independent pathways.Dev Biol. 2000;221:404-418.
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.Nat Genet. 1997;15:356-362.
Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.Cancer Res. 1997;57:2124-2129.
Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.J Natl Cancer Inst. 1999;91:1922-1932.
Davies MP, Gibbs FE, Halliwell N, Joyce KA, Roebuck MM, Rossi ML, Salisbury J, Sibson DR, Tacconi L, Walker C. Mutation in the PTEN/MMAC1 gene in archival low grade and high grade gliomas.Br J Cancer. 1999;79:1542-1548.
Kondo K, Yao M, Kobayashi K, Ota S, Yoshida M, Kaneko S, Baba M, Sakai N, Kishida T, Kawakami S. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines.Int J Cancer. 2001;91:219-224.
Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, Demers GW, Wills KN, Shabram PW, Bolen JB, Tavtigian SV. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer.Cancer Res. 1998;58:2331-2334.
Gu J, Tamura M, Yamada KM. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways.J Cell Biol. 1998;143:1375-1383.
Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.J Biol Chem. 1998;273:13375-13378.
Khaleghpour K, Li Y, Banville D, Yu Z, Shen SH. Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma.Carcinogenesis. 2004;25:241-248.
Arico S, Petiot A, Bauvy C, Dubbelhuis PF, Meijer AJ, Codogno P, Ogier-Denis E. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway.J Biol Chem. 2001;276:35243-35246.
Tamura M, Gu J, Danen EH, Takino T, Miyamoto S, Yamada KM. PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway.J Biol Chem. 1999;274:20693-20703.
Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase.Trends Cell Biol. 1999;9:125-128.
Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.Cell. 1999;99:323-334.
Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.Proc Natl Acad Sci USA. 1999;96:10182-10187.
Haier J, Nicolson GL. Time-dependent dephosphorylation through serine/threonine phosphatases is required for stable adhesion of highly and poorly metastatic HT-29 colon carcinoma cell lines to collagen.Anticancer Res. 2000;20:2265-2271.
Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers.Cancer Res. 2004;64:3014-3021.
Zhou XP, Kuismanen S, Nystrom-Lahti M, Peltomaki P, Eng C. Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors.Hum Mol Genet. 2002;11:445-450.
Laghi L, Bianchi P, Roncalli M, Malesci A. Re: Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.J Natl Cancer Inst. 2004;96:1402-3; author reply 1403-1404.
Brennetot C, Buhard O, Jourdan F, Flejou JF, Duval A, Hamelin R. Mononucleotide repeats BAT-26 and BAT-25 accurately detect MSI-H tumors and predict tumor content: implications for population screening.Int J Cancer. 2005;113:446-450.
Romanowicz-Makowska H, Smolarz B, Langner E, Kozlowska E, Kulig A, Dziki A. Analysis of microsatellite instability and BRCA1 mutations in patients from hereditary nonpolyposis colorectal cancer (HNPCC) family.Pol J Pathol. 2005;56:21-26.